427 related articles for article (PubMed ID: 26504152)
1. Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes.
Komrokji RS; List AF
Ann Oncol; 2016 Jan; 27(1):62-8. PubMed ID: 26504152
[TBL] [Abstract][Full Text] [Related]
2. Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion.
Sánchez-García J; Del Cañizo C; Lorenzo I; Nomdedeu B; Luño E; de Paz R; Xicoy B; Valcárcel D; Brunet S; Marco-Betes V; García-Pintos M; Osorio S; Tormo M; Bailén A; Cerveró C; Ramos F; Diez-Campelo M; Such E; Arrizabalaga B; Azaceta G; Bargay J; Arilla MJ; Falantes J; Serrano-López J; Sanz GF;
Br J Haematol; 2014 Jul; 166(2):189-201. PubMed ID: 24716538
[TBL] [Abstract][Full Text] [Related]
3. Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS.
List AF; Bennett JM; Sekeres MA; Skikne B; Fu T; Shammo JM; Nimer SD; Knight RD; Giagounidis A;
Leukemia; 2014 May; 28(5):1033-40. PubMed ID: 24150217
[TBL] [Abstract][Full Text] [Related]
4. Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence.
Oliva EN; Lauseker M; Aloe Spiriti MA; Poloni A; Cortelezzi A; Palumbo GA; Balleari E; Sanpaolo G; Volpe A; Ricco A; Ronco F; Alati C; D'Errigo MG; Santacaterina I; Kündgen A; Germing U; Latagliata R
Cancer Med; 2015 Dec; 4(12):1789-97. PubMed ID: 26376955
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-Analysis.
Lian XY; Zhang ZH; Deng ZQ; He PF; Yao DM; Xu ZJ; Wen XM; Yang L; Lin J; Qian J
PLoS One; 2016; 11(11):e0165948. PubMed ID: 27824902
[TBL] [Abstract][Full Text] [Related]
6. Lenalidomide: a review of its use in patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndrome associated with 5q chromosome deletion.
Syed YY; Scott LJ
Drugs; 2013 Jul; 73(11):1183-96. PubMed ID: 23824699
[TBL] [Abstract][Full Text] [Related]
7. Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study.
Giagounidis A; Mufti GJ; Mittelman M; Sanz G; Platzbecker U; Muus P; Selleslag D; Beyne-Rauzy O; te Boekhorst P; del Cañizo C; Guerci-Bresler A; Nilsson L; Lübbert M; Quesnel B; Ganser A; Bowen D; Schlegelberger B; Göhring G; Fu T; Benettaib B; Hellström-Lindberg E; Fenaux P
Eur J Haematol; 2014 Nov; 93(5):429-38. PubMed ID: 24813620
[TBL] [Abstract][Full Text] [Related]
8. Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents.
Santini V; Almeida A; Giagounidis A; Gröpper S; Jonasova A; Vey N; Mufti GJ; Buckstein R; Mittelman M; Platzbecker U; Shpilberg O; Ram R; Del Cañizo C; Gattermann N; Ozawa K; Risueño A; MacBeth KJ; Zhong J; Séguy F; Hoenekopp A; Beach CL; Fenaux P
J Clin Oncol; 2016 Sep; 34(25):2988-96. PubMed ID: 27354480
[TBL] [Abstract][Full Text] [Related]
9. The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes: Results From the MDS-005 Study.
Santini V; Almeida A; Giagounidis A; Platzbecker U; Buckstein R; Beach CL; Guo S; Altincatal A; Wu C; Fenaux P
Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):136-144.e7. PubMed ID: 29429612
[TBL] [Abstract][Full Text] [Related]
10. Lenalidomide--a transforming therapeutic agent in myelodysplastic syndromes.
List A
Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S302-4. PubMed ID: 19778857
[TBL] [Abstract][Full Text] [Related]
11. Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes.
Giagounidis A; Mufti GJ; Fenaux P; Germing U; List A; MacBeth KJ
Ann Hematol; 2014 Jan; 93(1):1-11. PubMed ID: 24018623
[TBL] [Abstract][Full Text] [Related]
12. Lenalidomide in patients with red blood cell transfusion-dependent myelodysplastic syndrome and del(5q): a single-centre "real-world" experience.
Cerqui E; Pelizzari A; Schieppati F; Borlenghi E; Pagani C; Bellotti D; Lamorgese C; Boiocchi L; Sottini A; Imberti L; Rossi G
Leuk Lymphoma; 2015; 56(11):3129-34. PubMed ID: 25811676
[TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q).
Fenaux P; Giagounidis A; Selleslag D; Beyne-Rauzy O; Mittelman M; Muus P; Nimer SD; Hellström-Lindberg E; Powell BL; Guerci-Bresler A; Sekeres MA; Deeg HJ; Del Cañizo C; Greenberg PL; Shammo JM; Skikne B; Yu X; List AF
J Hematol Oncol; 2017 Jun; 10(1):131. PubMed ID: 28651604
[TBL] [Abstract][Full Text] [Related]
14. Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis.
Kuendgen A; Lauseker M; List AF; Fenaux P; Giagounidis AA; Brandenburg NA; Backstrom J; Glasmacher A; Hasford J; Germing U;
Leukemia; 2013 Apr; 27(5):1072-9. PubMed ID: 23257782
[TBL] [Abstract][Full Text] [Related]
15. Lenalidomide for del(5q) and non-del(5q) myelodysplastic syndromes.
Giagounidis AA
Semin Hematol; 2012 Oct; 49(4):312-22. PubMed ID: 23079061
[TBL] [Abstract][Full Text] [Related]
16. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
Göhring G; Giagounidis A; Büsche G; Kreipe HH; Zimmermann M; Hellström-Lindberg E; Aul C; Schlegelberger B
Ann Hematol; 2010 Apr; 89(4):365-74. PubMed ID: 19855965
[TBL] [Abstract][Full Text] [Related]
17. Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy.
Oliva EN; Latagliata R; Laganà C; Breccia M; Galimberti S; Morabito F; Poloni A; Balleari E; Cortelezzi A; Palumbo G; Sanpaolo G; Volpe A; Specchia G; Finelli C; D'Errigo MG; Rodà F; Alati C; Alimena G; Nobile F; Aloe Spiriti MA
Leuk Lymphoma; 2013 Nov; 54(11):2458-65. PubMed ID: 23432724
[TBL] [Abstract][Full Text] [Related]
18. Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond.
Talati C; Sallman D; List A
Semin Hematol; 2017 Jul; 54(3):159-166. PubMed ID: 28958290
[TBL] [Abstract][Full Text] [Related]
19. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
Nimer SD
J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711
[TBL] [Abstract][Full Text] [Related]
20. Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes.
Sekeres MA; Maciejewski JP; Giagounidis AA; Wride K; Knight R; Raza A; List AF
J Clin Oncol; 2008 Dec; 26(36):5943-9. PubMed ID: 19018091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
